Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku N. Yamamoto N, et al. Among authors: koh y. Ann Oncol. 2013 Jun;24(6):1653-9. doi: 10.1093/annonc/mdt014. Epub 2013 Feb 14. Ann Oncol. 2013. PMID: 23413279 Free article. Clinical Trial.
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Lee JK, Shin JY, Kim S, Lee S, Park C, Kim JY, Koh Y, Keam B, Min HS, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS, Lee SH, Kim JI. Lee JK, et al. Among authors: koh y. Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4. Ann Oncol. 2013. PMID: 23559152 Free article.
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas.
Song Y, Yoon DH, Yang H, Cao J, Ji D, Koh Y, Jing H, Eom H, Kwak J, Lee W, Lee J, Shin H, Jin J, Wang M, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: koh y. Ann Oncol. 2023 Nov;34(11):1055-1063. doi: 10.1016/j.annonc.2023.08.013. Epub 2023 Sep 9. Ann Oncol. 2023. PMID: 37673210 Free article. Clinical Trial.
Clinical outcomes of radiation-based locoregional therapy in locally advanced head and neck squamous cell carcinoma patients not responding to induction chemotherapy.
Lim Y, Keam B, Koh Y, Kim TM, Lee SH, Hah JH, Kwon TK, Kim DW, Wu HG, Sung MW, Heo DS, Kim KH. Lim Y, et al. Among authors: koh y. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jul;116(1):55-60. doi: 10.1016/j.oooo.2013.02.007. Epub 2013 Apr 6. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013. PMID: 23570665
3,236 results